About this Webinar:
This session, ‘Using Artificial Intelligence (AI) to support Quantitative Digital Pathology in R&D’, was live on Wednesday 17th November 2021. You can re-watch the full webinar including the Q&A above.
Presented by OracleBio’s Chief Scientific Officer, Lorcan Sherry, it covered:
- Using AI Deep Learning to improve image analysis accuracy and turn-around time in a pre-clinical tumor IHC study
- Integrating clinical pathologist input in development and validation of a Deep Learning Tissue Classifier App
- Advantages of implementing Deep Learning for tissue segmentation and cell detection in multiplex IF studies
- and more…
Chief Scientific Officer
As co-founder and Chief Scientific Officer at OracleBio, Lorcan has helped establish the company as a market leader within its field, supporting the digital pathology programmes of major Pharma and Biotech companies around the globe.
Day to day, Lorcan oversees a team of image analysis scientists and pathologists responsible for the execution of Client image analysis R&D studies, while further driving the adoption of innovative techniques and processes to improve the quality and efficiency of our services.
More from OracleBio:
High ICOS/FOXP3 Tregs Content in the Tumor Microenvironment is Associated with Poorer Survival in Patients with Hepatocellular Carcinoma
OracleBio data quantifying ICOS and FoxP3 dual IHC in clinical HCC samples is presented on a collaborative poster at the AACR 2020 Virtual Annual Meeting. The poster, produced in collaboration with Kymab and the National Taiwan University Hospital, explores the...
Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration
OracleBio presented a poster at the Society for Immunotherapy of Cancer Annual Meeting 2019 on the 6th – 10th November. The poster is entitled ‘Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to...
Characterization of Anti-CTLA-4 Effects on Tumor Growth and Immune Microenvironment in a Syngeneic CT26.WT Colon Carcinoma Mouse Model
In collaboration with Pharmatest, OracleBio presented a poster at the AACR Annual Meeting 2019, which took place from the 29th of March to the 3rd of April 2019. The poster is entitled ‘Characterization of Anti-CTLA-4 Effects on Tumor Growth and Immune...
Find out more about our Multiplex IF Analysis
OracleBio's Quantitative Digital Pathology Services
Stay up to date with OracleBio
Sign up to our mailing list to stay informed about news, webinars, events and more